First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.

The once daily tablet is expected to reach US patients in October 2026.

The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.

Researchers evaluate peer-reviewed literature on interventions to improve vaccine uptake among thousands of US adults studied between 2010 and 2015.

Infectious disease readiness depends on rehearsed workflows, bidirectional public health communication, and rapid access to care.

Pharmacist pain clinics typically focus on comprehensive medication management involving the entire patient scenario.

A case shows a suspected recurrence of pneumococcal disease that ended with removal of one cochlear implant and replacement of the other.

Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.